Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · IEX Real-Time Price · USD
2.900
-0.040 (-1.36%)
At close: Jul 19, 2024, 4:30 PM
3.000
+0.100 (3.45%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $435.47M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $109.98M with 2.17% year-over-year growth. In the year 2023, Organogenesis Holdings had annual revenue of $433.14M.
Revenue (ttm)
$435.47M
Revenue Growth
-5.62%
P/S Ratio
0.88
Revenue / Employee
$505,190
Employees
862
Market Cap
384.46M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | 193.45M | -5.06M | -2.55% |
| Dec 31, 2017 | 198.51M | 59.78M | 43.09% |
| Dec 31, 2016 | 138.73M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Revance Therapeutics | 236.65M |
| AxoGen | 163.73M |
| Sight Sciences | 81.50M |
| uniQure | 19.00M |
| Precigen | 5.44M |
| Lyell Immunopharma | 68.00K |
ORGO News
- 6 days ago - Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024 - GlobeNewsWire
- 6 weeks ago - Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference - GlobeNewsWire
- 2 months ago - Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis - GlobeNewsWire
- 3 months ago - Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 - GlobeNewsWire
- 3 months ago - Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case - GlobeNewsWire
- 5 months ago - Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance - GlobeNewsWire
- 5 months ago - Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference - GlobeNewsWire
- 5 months ago - Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024 - GlobeNewsWire